A Phase II Randomized, Placebo Controlled, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients Upon Discharge or Following Hospitalization for Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2017
At a glance
- Drugs QGC 001 (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUID-HF
- Sponsors Quantum Genomics
- 10 Jun 2017 Biomarkers information updated
- 15 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 15 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.